Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin Effects on Atherosclerosis Markers in Type 2 Diabetes
NCT03907423Completed
- Sponsor
- Rehab Werida
- Start
- Apr 2019
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Rosuvastatin with Placebo (2 arms). Primary endpoints: Serum levels of Fetuin-A at 3 months and Serum levels of Sortilin at 3 months. Started Apr 2019; status: completed.
02
Drugs
rosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03907423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907423.